AMA kratom policy needs regulation, not a 7-OH ban
An American Medical Association (AMA) policy from June 9, 2026, calls for prohibiting the sale, distribution, and marketing of concentrated 7-hydroxymitragynine (7-OH) products while supporting surveillance, additional research, and other public health measures for kratom, according to the AMA press release and the AMA House of Delegates report. This policy raises an uncomfortable question: Was the AMA duped on 7-OH?
The question is particularly relevant …
AMA kratom policy needs regulation, not a 7-OH ban
